Veradermics, Inc
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
MANE$148.44+3.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (unaudited)
Condensed Consolidated Statements of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| (in thousands) | 2026 | 2025 |
| Cash flows from operating activities: | ||
| Net loss | $(27,232) | $(12,400) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 5,259 | 213 |
| Non-cash research and development services | 621 | 357 |
| Net accretion of discount/premium on debt securities | (73) | (13) |
| Other | 6 | 2 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 4,360 | 79 |
| Interest receivable on marketable securities | (1,499) | — |
| Accounts payable | (1,055) | (686) |
| Accrued expenses | (1,373) | (862) |
| Other long term assets | (174) | — |
| Other current liabilities and lease liabilities | (8) | (7) |
| Net cash used in operating activities | (21,168) | (13,317) |
| Cash flows from investing activities: | ||
| Purchase of property, plant and equipment | — | (19) |
| Purchases of marketable securities | (122,988) | (15,731) |
| Maturities of marketable securities | 21,689 | — |
| Net cash used in investing activities | (101,299) | (15,750) |
| Cash flows from financing activities: | ||
| Issuance of Series B preferred stock, net of issuance costs paid | — | 8,423 |
| Initial public offering, net of issuance costs paid | 269,102 | — |
| Exercise of stock options | 11 | — |
| Net cash provided by financing activities | 269,113 | 8,423 |
| Net increase (decrease) in cash and cash equivalents | 146,646 | (20,644) |
| Cash and cash equivalents—beginning of period | 21,766 | 53,084 |
| Cash and cash equivalents—end of period | $168,412 | $32,440 |
| Supplemental schedule of noncash activities: | ||
| Unrealized loss on marketable securities | $(584) | $— |
| Right-of-use asset exchanged for lease liabilities | $— | $90 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.